Sirolimus Based Immunosuppression for Patients Undergoing Kidney Transplantation in the Eurotransplant Senior Program (ESP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00461357|
Recruitment Status : Unknown
Verified April 2007 by Medical University of Vienna.
Recruitment status was: Active, not recruiting
First Posted : April 18, 2007
Last Update Posted : April 18, 2007
The Eurotransplant Senior Program (ESP) started in 1999 with local allocation of kidneys from deceased donors elder than 65 years to recipients elder than 65 years. The requirements for immunosuppression in this group of patients are high due to the large amount of comorbidities.
This prospective randomized trial compared the standard immunosuppressive protocol based on cyclosporine A (CyA) used at our center within the ESP, to a calcineurin inhibitor-free protocol based on sirolimus (SRL).
The aim of this study is to investigate the effect of a CNI-free therapy on the function of elderly kidneys 6 months post transplantation, measured by GFR.
|Condition or disease|
|Kidney Function After Transplantation Outcome After Kidney Transplantation|
|Study Type :||Observational|
|Enrollment :||48 participants|
|Official Title:||Outcome After Renal Transplantation of a Randomized Prospective Trial in the Eurotransplant Senior Program|
|Study Start Date :||January 2003|
|Estimated Study Completion Date :||December 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00461357
|Principal Investigator:||Ferdinand Muehlbacher, MD Professor||Medical University of Vienna; Department of Transplantation|